Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis

Ticker
EQL.ST

Price
61.50
Stock movement up
+0.50 (0.82%)
Company name
EQL Pharma AB
Exchange
(ST
,
Currency
SEK
)
Sector
Healthcare >
Drug Manufacturers - Specialty & Generic
Market cap
1.82B
Ent value
2.29B
Price/Sales
5.35
Price/Book
6.73
Div yield
4.69%
Div growth
8.43%
Growth years
1
FCF payout
-
Trailing P/E
55.53
Forward P/E
27.83
PEG
-
EPS growth
-
1 year return (CAGR)
56.49%
3 year return (CAGR)
69.63%
5 year return (CAGR)
41.54%
10 year return (CAGR)
-
Last updated: 2026-03-03

DIVIDENDS

Dividend yield - 5y

Dividend yield data
Dividend per share2.88
Dividend yield4.69%
Payout frequencyQuarterly
Maximum yield6.01%
Average yield0.39%
Minimum yield-
Discount to avg yield91.58%
Upside potential1088.20%
Yield as % of max yield78.05%

Yield distribution (inverse percentile) - 5y

Yield distribution data
Dividend yield4.69%
Current yield distribution6.11%
Yield at 100% (Min)-
Yield at 90%-
Yield at 80%-
Yield at 50% (Median)-
Yield at 20%-
Yield at 10%-
Yield at 0% (Max)6.01%

Dividend per share

Dividend per share data
Years of growth1 years
CCC status-
Dividend per share2.88
Payout frequencyQuarterly
Ex-div date22 Dec 2022
EPS (TTM)1.11
EPS (1y forward)2.21
EPS growth (5y)-
EPS growth (5y forward)-

Dividend growth

Please create a free account or log in to access this chart
Dividend growth data
EQL.STS&P500
DGR MR33.61%-13.74%
DGR TTM10.93%6.60%
DGR 3 years9.55%7.31%
DGR 5 years8.43%4.69%
DGR 10 years9.44%6.30%
DGR 15 years-8.16%
Time since last change announced1169 days
EPS growth (5y)-
EPS growth (5y forward)-

Payout ratio

Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM--
Average--
Forward130.44%-

VALUATION

Valuation Ratios

Valuation Ratios data
Trailing P/E55.53
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Valuation (Sales/Book Value) data
Price to Sales5.35
Price to Book6.73
EV to Sales6.74

FINANCIALS

Per share

Per share data
Current share count29.53M
EPS (TTM)1.11
FCF per share (TTM)-8.77

Income statement

Income statement data
Revenue (TTM)339.37M
Gross profit (TTM)142.95M
Operating income (TTM)62.96M
Net income (TTM)32.70M
EPS (TTM)1.11
EPS (1y forward)2.21

Margins

Margins data
Gross margin (TTM)42.12%
Operating margin (TTM)18.55%
Profit margin (TTM)9.64%

Balance Sheet

Please create a free account or log in to access this chart
Balance Sheet data
Cash72.67M
Net receivables81.37M
Total current assets376.73M
Goodwill0.00
Intangible assets431.39M
Property, plant and equipment0.00
Total assets813.54M
Accounts payable45.33M
Short/Current long term debt0.00
Total current liabilities174.37M
Total liabilities543.76M
Shareholder's equity269.78M
Net tangible assets0.00

Cash flow

Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-3.69M
Capital expenditures (TTM)255.38M
Free cash flow (TTM)-259.06M
Dividends paid (TTM)0.00

Financial returns

Please create a free account or log in to access this chart
Financial returns data
Return on Equity12.12%
Return on Assets4.02%
Return on Invested Capital5.35%
Cash Return on Invested Capital-42.38%

STOCK INFORMATION

Stock chart

Stock price data
Open61.10
Daily high61.60
Daily low59.90
Daily Volume22K
All-time high69.90
1y analyst estimate80.00
Beta0.41
EPS (TTM)1.11
Dividend per share2.88
Ex-div date22 Dec 2022
Next earnings date-

Downside potential

Downside potential data
EQL.STS&P500
Current price drop from All-time high-12.02%-1.82%
Highest price drop-61.21%-56.47%
Date of highest drop6 Mar 20159 Mar 2009
Avg drop from high-24.16%-10.84%
Avg time to new high31 days12 days
Max time to new high360 days1805 days
COMPANY DETAILS
EQL.ST (EQL Pharma AB) company logo
Marketcap
1.82B
Marketcap category
Small-cap
Description
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.
Employees
55
Website
https://www.eqlpharma.com
Investor relations
-
SEC filings
EQL.ST SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
UNDERSTAND THE BUSINESS
COMPANY NEWS
All newsPress releases
EQL Pharma (OM:EQL) Margin Miss Challenges Bullish Growth Narrative Despite Strong Forecasts
EQL Pharma (OM:EQL) is forecasting robust growth, with earnings expected to climb 59.6% per year and revenue set to increase 30.4% per year, both well ahead of broader Swedish market expectations. How...
November 6, 2025
EQL Pharma AB (OSTO:EQL) Q2 2026 Earnings Call Highlights: Navigating Supply Chain Challenges ...
Despite a challenging quarter with supply chain disruptions, EQL Pharma AB (OSTO:EQL) focuses on strategic launches and market expansions to drive future growth.
November 5, 2025
Disclaimer
Skyfall Technology OÜ assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness. Please also note, that any action you take upon the information provided on this website is strictly at your own risk. This website is intended to be used and must be used for informational purposes only and you should take independent financial advice from a professional and independently research and verify everything you see on the site.
Menu
HomePortfolio ManagementCompany ScreenerGreen InvestmentExchangesAbout usFeatured ArticlesContact Us
Language
ENHUNOSVDAFIESDENLFRITPTPLCSSKROELTRRUAF
© 2026 Skyfall Technology OÜ All Rights Reserved